

B.25-C4.

CASE 4-30188E

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV 365588 782 US
Express Mail Label Number

March 24, 2004
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

FUJIMOTO ET AL.

APPLICATION NO: 10/728,244

FILED: DECEMBER 4, 2003

FOR: CERTAIN 5-ALKYL-2-ARYLAMINOPHENYLACETIC ACIDS AND
DERIVATIVES

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is being filed within three months of the filing date of the application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in prior Application Nos. 10,201,336 filed July 23, 2002, 09/139,254 filed August 25, 1998, 09/722,767 filed November 27, 2000 and 09/950,957 filed September 13, 2001, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'David E. Wildman', written over a horizontal line.

David E. Wildman
Attorney for Applicants
Reg. No. 40,226

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-7954

Date: *march 24, 2004*

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)


 ATTY. DOCKET NO.
 4-30188E/USN
 APPLICATION NO.
 10/728,244
 APPLICANT
 FUJIMOTO ET AL.
 FILING DATE
 December 4, 2003

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	3,531,493	9/29/70	Gittos et al.			
	AB	3,558,690	1/26/71	Sallmann et al.			
	AC	3,652,762	3/28/72	Sallmann et al.			
	AD	3,895,063	7/15/75	Sallman et al.			
	AE	4,173,577	11/6/79	Sallmann et al.			
	AF	4,548,952	10/22/85	Antonio V. Casas			
	AG	5,958,978	9/28/99	Yamazaki et al.			
	AH						
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	<u>TRANSLATION</u>	
							YES	NO
	AM	DE 3445011 A1	6/13/85	Germany (and translation)			<input checked="" type="checkbox"/>	<input type="checkbox"/>
	AN	WO 94/04484	3/3/94	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 96/00716	1/11/96	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 97/09977	3/20/97	PCT (and translation)			<input checked="" type="checkbox"/>	<input type="checkbox"/>
	AQ	EP 865,788 A1	9/23/98	Europe			<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Sircar J.C., Curr.Opin.Invest.Drugs, Vol. 2 (4), pp. 403-407 (1993)
	AS	Englehardt G., Z. Rheumatol, Vol. 53, Suppl. 1, pg. 68 (1994)
	AT	Englehardt G., Eur. J., Clin. Pharmacology, Vol. 47 (No. 1) pg. A98 (1994)

EXAMINER**DATE CONSIDERED**


*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30188E/USN
APPLICATION NO.
10/728,244
APPLICANT
FUJIMOTO ET AL.
FILING DATE
December 4, 2003

Group

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Brit. J. Pharmacol., Vol. 112, Proc. Suppl., pg. 183P (1994)
AB	Klein T. et al., Biochemical Pharmacology, Vol. 48, No. 8, pp 1605-1610 (1994)
AC	Mitchell J.A. et al., Proc.Natl.Acad.Sci.USA, Vol. 90, pp. 11693-11697 (1994)
AD	Pallapies D. et al., Life Sciences, Vol. 57, No. 2, pp. 83-89 (1995)
AE	Pairat M. et al., Proceedings of a conference, October 10-11, 1995, "Improved Non-Steroid Anti-Inflammatory Drugs COX-2 Enzyme Inhibitors", Edited by John Vane et al., pp. 103-119
AF	Seibert K. et al., Advances in Prostaglandin, Thromboxane, and Leukotriene Research, Vol. 23, pg. 125-127 (1995)
AG	Englehardt G., Br.J.Rheumatol. Vol. 34, Abstr. Suppl. 1, pg. 48 (1995)
AH	Glaser K.B., Inflammopharmacology, Vol. 3, pp. 335-345, (1995)
AI	Gierse J.K. et al., Biochem.J., Vol. 305, pp. 479-484 (1995)
AJ	Prasit P. et al., Med.Chem.Res., Vol. 5, pp. 364-374 (1995)
AK	Chan Chi-Chung et al., Journ.Pharmacology and Experimental Therapeutics, Vol. 274, pp. 1531-1537 (1995)
AL	Grossman C.J. et al., Inflammation Res., Vol. 44, pp. 253-257 (1995)
AM	Glaser K.B. et al., Inflammation Res., Vol. 44, Suppl. 3, pg. S276 (1995)
AN	Gamage et al., Anti-Cancer Drug Design (Vol. 7, pgs. 403-414 (1992).

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30188E/USN
APPLICATION NO.
10/728,244
APPLICANT
FUJIMOTO ET AL.
FILING DATE
December 4, 2003

Group

**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Grossman C.J. et al., Inflammation Res., Vol. 44, Suppl. 3, pg. S272 (1995)
AB	Warner T.D. et al., Inflammation Res., Vol. 44, Suppl. 3, pg. S274 (1995)
AC	Terlain B. et al., Presse Med., Vol. 24, No. 10, pp. 491-496 (1995)
AD	Gierse J.K. et al., Journ.Biological Chemistry, Vol. 271, No. 26, pp. 15810-15814 (1996)
AE	Englehardt G., Z. Rheumatol. Vol. 55, Suppl. 1, pg. 112 (1996)
AF	Distel M. et al., British Jour. of Rheumatology, Vol. 35 (suppl. 1) pp. 68-77 (1996)
AG	Churchill L. et al., Inflammopharmacology, Vol. 4, pp. 125-135 (1996)
AH	Steinhilber D., Pharm.Ztg., Vol. 141(37), pp. 11-18 (1996)
AI	Vane J.R. et al., Scan.J.Rheumatol. Vol. 25 (Suppl. 102) pp. 9-21 (1996)
AJ	Matsushita M. et al., Inflamm.Res., Vol. 46, pp. 461-466 (1997)
AK	Englehardt G. et al., Biochemical Pharmacology, Vol. 51, pp. 21-28 (1996)
AL	Cromlish W.A. et al., Biochemical Pharmacology, Vol. 52, pp. 1777-1785 (1996)
AM	Brideau C. et al., Inflamm.Res., Vol. 45, pp. 68-74 (1996)
AN	Moser et al., J. Med. Chem., Vol. 33, pgs. 2358-2368 (1990)

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
4-30188E/USN
APPLICATION NO.
10/728,244
APPLICANT
FUJIMOTO ET AL.
FILING DATE
December 4, 2003

Group



OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AA	Patrignani P. et al., Journal of Physiology and Pharmacology, Vol. 48, 4, pp. 623-631 (1997)
AB	Pairat M. et al., Proceedings of a conference on March 20-21, 1997, "Selective COX-2 Inhibitors Pharmacology, Clinical Effects and Therapeutic Potential" Edited by John Vane et al., pp. 27-46
AC	Dammann H.G. et al., Clinical Pharmacology & Therapeutics, Vol. 61, pg. 162 (1997)
AD	Pairat M. et al., Infamm. Res., Vol. 47, Suppl. 2, pp. S93-S101 (1998)
AE	Silvestre J. et al., Drugs of the Future, Vol. 23(6), pp. 598-601 (1998)
AF	Giuliano F. et al., Brit. J.Pharmacol., Vol. 125, Suppl. 1, 35P (1998)
AG	Simmons D.L. et al., Journal of Lipid Mediators, Vol. 6, pp. 113-117 (1993)
AH	Japanese Pharmacol. Ther., Vol. 25, No. 8, pp. 2131-2136 (1997)
AI	Japanese Journal of Inflammation, Vol. 15, No. 5, pp. 409-411 (1995)
AJ	Cryer B. et al., Amer.J.Med., Vol. 104, No. 5, pp. 413-421 (1998)
AK	Chemical Abstract 118:80787 (1993)
AL	Chemical Abstracts 104: 109230 (Abstract of DE 3445011)
AM	Griswold et al., Medicinal Research Reviews, Vol. 16, No. 2, pgs. 181-206 (1996)
AN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.